Nuchev Pty Ltd (AU:NUC)
ASX:NUC
Top Page
Nuchev Pty Ltd
(Sydney:NUC)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$0.18
▲(50.00% Upside)
Action:ReiteratedDate:03/27/26
The score is held back primarily by weak financial quality—ongoing losses and negative operating/free cash flow—despite strong top-line growth and conservative leverage. Technicals are supportive with a clear uptrend and positive momentum, but valuation remains constrained by negative earnings and no stated dividend yield.
Positive Factors
Revenue Growth
A sustained ~45% revenue expansion demonstrates robust market demand and effective commercial execution across channels. Over a 2-6 month horizon this trend supports scale benefits, helps absorb fixed costs, and provides a runway for margin recovery if cost discipline and mix improvements continue.
Negative Factors
Persistent Unprofitability
Ongoing negative EBIT and net margins indicate structural profitability issues that limit retained earnings and reinvestment capacity. Without sustained margin improvement through pricing, cost control, or product mix shifts, losses are likely to persist and constrain long-term financial health.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A sustained ~45% revenue expansion demonstrates robust market demand and effective commercial execution across channels. Over a 2-6 month horizon this trend supports scale benefits, helps absorb fixed costs, and provides a runway for margin recovery if cost discipline and mix improvements continue.
Read all positive factors
Nuchev Pty Ltd (NUC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$28.23M
Dividend YieldN/A
Average Volume (3M)7.76K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth102.21%
EPS Growth69.47%
CountryAU
EmployeesN/A
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)-0.02
Shares Outstanding156,818,770
10 Day Avg. Volume3,027
30 Day Avg. Volume7,761
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.82
Price to Sales (P/S)0.89
P/FCF Ratio-5.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nuchev Pty Ltd Business Overview & Revenue Model
Company Description
Nuchev Limited, a health and nutrition solutions company, produces, markets, and sells goat milk-based infant formula and nutritional products to consumers in Australia, China, and Vietnam. The company provides toddler nutrition, goat nutritional ...
How the Company Makes Money
Nuchev makes money primarily by selling its branded nutrition products (most notably goat milk–based infant formula and children’s nutrition products) to customers via (1) domestic retailers and pharmacies, (2) e-commerce/direct-to-consumer channe...
Nuchev Pty Ltd Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.27M | 22.94M | 11.34M | 8.79M | 9.72M | 10.90M |
| Gross Profit | 7.17M | 10.86M | 3.63M | 1.90M | 2.78M | 3.20M |
| EBITDA | -4.18M | -3.73M | -7.18M | -8.57M | -10.88M | -12.40M |
| Net Income | -4.58M | -3.82M | -7.32M | -8.81M | -11.11M | -13.27M |
Balance Sheet | ||||||
| Total Assets | 17.39M | 17.39M | 20.09M | 15.32M | 17.75M | 28.31M |
| Cash, Cash Equivalents and Short-Term Investments | 3.11M | 3.61M | 7.61M | 7.49M | 5.13M | 14.53M |
| Total Debt | 529.14K | 392.63K | 322.85K | 284.14K | 154.12K | 286.33K |
| Total Liabilities | 6.63M | 6.16M | 5.34M | 2.51M | 1.92M | 1.62M |
| Stockholders Equity | 10.76M | 11.23M | 14.75M | 12.82M | 15.83M | 26.69M |
Cash Flow | ||||||
| Free Cash Flow | -3.62M | -3.93M | -3.74M | -3.38M | -11.62M | -9.86M |
| Operating Cash Flow | -3.48M | -3.74M | -3.73M | -3.26M | -11.61M | -9.49M |
| Investing Cash Flow | -169.48K | -138.16K | -2.19M | -126.83K | -914.20K | 411.90K |
| Financing Cash Flow | 1.81M | -115.53K | 6.06M | 5.78M | -118.28K | 14.16M |
Nuchev Pty Ltd Technical Analysis
Positive
0.12
Price Trends
0.13
Positive
0.14
Positive
0.15
Positive
Market Momentum
<0.01
Negative
67.97
Neutral
72.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NUC, the sentiment is Positive. The current price of 0.12 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.13, and below the 200-day MA of 0.15, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 67.97 is Neutral, neither overbought nor oversold. The STOCH value of 72.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NUC.
Nuchev Pty Ltd Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
54 Neutral | AU$35.84M | 22.20 | -53.68% | ― | -15.07% | 29.45% | |
50 Neutral | AU$28.23M | -2.06 | -41.69% | ― | 102.21% | 69.47% | |
41 Neutral | AU$5.53M | -0.92 | -92.72% | ― | 39.53% | 49.99% | |
40 Underperform | AU$30.48M | -0.37 | 19.78% | ― | 1.03% | -52.56% | |
40 Underperform | AU$26.02M | -5.27 | -19.17% | ― | 13.92% | 36.28% |
* Consumer Defensive Sector Average
AU:NUC
Nuchev Pty Ltd
0.18
0.00
0.00%
AU:NOU
Noumi Limited
0.11
-0.03
-21.43%
AU:AHF
Australian Dairy Nutritionals Group
0.03
-0.02
-40.00%
AU:WNX
Wellnex Life Ltd
0.08
-0.40
-83.37%
AU:MBH
Maggie Beer Holdings Ltd.
0.08
0.02
29.03%
Nuchev Pty Ltd Corporate Events
Nuchev Issues 767,442 Unquoted Share Rights Under Employee Incentive Plan
Mar 20, 2026
Nuchev Limited has notified the market of the issue of 767,442 unquoted share rights under its employee incentive scheme. The new securities, which are not intended to be quoted on the ASX, were issued on 16 March 2026 and reflect the company̵...
Nuchev shifts to full distribution model with H&S to boost margins and scale
Mar 3, 2026
Nuchev has entered a distribution agreement with HS Global to expand its role across the Brauer, Skin Physics and Rapid Loss brands, shifting from an agency-style arrangement to a full distribution model. The move gives Nuchev greater control over...
Nuchev Reaffirms Brand-Led Strategy in Half-Year Update
Feb 24, 2026
Nuchev Limited has reiterated its strategy of building trusted nutrition brands that families can rely on across multiple life stages, highlighting a disciplined focus on science-based product development and high product quality. The company unde...
Nuchev lifts revenue but widens loss as investment in goat milk nutrition growth continues
Feb 24, 2026
Nuchev reported a 12% rise in half-year revenue to $12.4 million and higher gross profit, driven mainly by its Australian retail channel and supported by practitioner and international markets, despite timing variability in shipments to Vietnam an...
Nuchev Grows Revenue but Half-Year Loss Deepens as Asset Base Thins
Feb 24, 2026
Nuchev Limited has reported a 12% increase in revenue to $12.38 million for the half-year ended 31 December 2025, but its net loss after tax widened by 48.2% to $2.34 million, reflecting higher costs or investment outlays despite growing sales. Th...
Nuchev Balances Softer Practitioner and International Sales With Solid Oli6 Performance and Positive Cash Flow
Jan 30, 2026
Nuchev reported second-quarter FY26 group sales revenue of $5.3 million, down 19% quarter-on-quarter and 13% year-on-year, with steady performance in its core Oli6 retail business offset by a sharp 48% quarterly decline in practitioner-channel rev...
Nuchev Director Increases Equity Stake via Incentive Plan Conversion
Jan 21, 2026
Nuchev Limited has disclosed a change in director Elizabeth Jean Smith’s interests following the exercise of unquoted share rights under the company’s Equity Incentive Plan, which was approved at the November 2024 AGM. Smith has receiv...
Nuchev Director Increases Shareholding Through Equity Incentive Plan
Jan 21, 2026
Nuchev Limited has announced a change in the interests of director Craig Silbery, following the exercise of unquoted share rights under the company’s Equity Incentive Plan. Silbery acquired 474,746 ordinary shares on 22 January 2026 through ...
Nuchev Director Increases Shareholding Through Equity Incentive Plan
Jan 21, 2026
Nuchev Limited has reported a change in director Ben Dingle’s interests following the exercise of unquoted share rights granted under the company’s Equity Incentive Plan in lieu of director fees. Dingle converted vested share rights va...
Nuchev Issues 1.23 Million New Shares Under Cleansing Notice
Jan 21, 2026
Nuchev Limited has issued 1,232,598 fully paid ordinary shares without a prospectus under the Corporations Act’s disclosure exemptions, confirming that it remains compliant with its continuous and financial reporting obligations and that the...
Nuchev Seeks ASX Quotation for 1.23 Million New Ordinary Shares
Jan 21, 2026
Nuchev Limited has applied to the ASX for quotation of 1,232,598 new ordinary fully paid shares, to be traded under its existing ticker NUC. The new securities, issued on 22 January 2026 following the exercise or conversion of existing options or ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.